
    
      Objectives of the Second Period: To provide the Levetiracetam treatment to subjects who are
      judged by the investigators to benefit from the long-term treatment and who are willing to
      continuously receive this drug. To continuously evaluate the safety of the Levetiracetam
      long-term administration at doses ranging from 20 mg/kg/day or 1000 mg/day to 60 mg/kg/day or
      3000 mg/day in subjects who completed the First Period of this study.
    
  